Organogenesis completes biologics license application for knee OA
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
CANTON, Mass. - Organogenesis Holdings Inc. (NASDAQ:ORGO) announced today the completion of a rolling Biologics License Application submission to the Food and Drug Administration for ReNu, a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis management. The $308 million market cap company’s shares have faced headwinds, declining 54% year-to-date to $2.40, though InvestingPro
Read full article at source